Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences to $80 from $90 and keeps an Overweight rating on the shares. The firm is updating its 2024 and 2025 revenues for all of its life science tools and labs coverage to account for lower expected spending on capital equipment and pharma services due to economic factors, including access to capital by companies and their customers and lower appetite for spending from pharma. Piper is also lowering its 2023 revenues for Fx.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EXAS:
- Rivian upgraded, Qorvo downgraded: Wall Street’s top analyst calls
- Exact Sciences upgraded to Overweight from Neutral at Piper Sandler
- DermTech, Natera can benefit from California biomarker law, says Craig-Hallum
- Exact Sciences initiated with an Outperform at Bernstein
- Exact Sciences’ testing laboratory selected by the National Cancer Institute
